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Abstract
Background:  Multidrug resistance (MDR) is a phenomenon that is often associated with
decreased intracellular drug accumulation in patient's tumor cells resulting from enhanced drug
efflux. It is related to the overexpression of a membrane protein, P-glycoprotein (Pgp-170), thereby
reducing drug cytotoxicity. A variety of studies have tried to find MDR modulators which increase
drug accumulation in cancer cells.
Methods:  In this study, natural curcuminoids, pure curcumin, demethoxycurcumin and
bisdemethoxycurcumin, isolated from turmeric (Curcuma longa Linn), were compared for their
potential ability to modulate the human MDR-1 gene expression in multidrug resistant human
cervical carcinoma cell line, KB-V1 by Western blot analysis and RT-PCR.
Results: Western blot analysis and RT-PCR showed that all the three curcuminoids inhibited MDR-
1 gene expression, and bisdemethoxycurcumin produced maximum effect. In additional studies we
found that commercial grade curcuminoid (approximately 77% curcumin, 17% demethoxycurcumin
and 3% bisdemthoxycurcumin) decreased MDR-1 gene expression in a dose dependent manner and
had about the same potent inhibitory effect on MDR-1 gene expression as our natural curcuminoid
mixtures.
Conclusion:  These results indicate that bisdemethoxycurcumin is the most active of the
curcuminoids present in turmeric for modulation of MDR-1 gene. Treatment of drug resistant KB-
V1 cells with curcumin increased their sensitivity to vinblastine, which was consistent with a
decreased MDR-1 gene product, a P-glycoprotein, on the cell plasma membrane. Although many
drugs that prevent the P-glycoprotein function have been reported, this report describes the
inhibition of MDR-1 expression by a phytochemical. The modulation of MDR-1 expression may be
an attractive target for new chemosensitizing agents.
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Background
The human MDR-1 gene encoding for MDR transporter
(Pgp-170) belongs to ATP-binding cassette (ABC) trans-
porter superfamily. The MDR-1 overexpression has been
reported in many tumors and in vitro selected drug-resist-
ant cell lines [1-4]. Uptake and/or efflux of isotope-
labelled drugs or rhodamine123 are frequently used for
functional assay of Pgp-170 in tumor cells. Several classes
of MDR modulators that inhibit Pgp-mediated efflux have
been identified. It has been found that the accumulation
of chemotherapy agents in tumor cells with overexpressed
Pgp-170 was significantly reduced as compared to the
MDR antagonist-treated tumor cells [5-7]. The other
approach for MDR regulation is the modulation of the
MDR-1  gene. Studies of the MDR-1  gene promoter
sequence suggest that inhibition of Pgp expression at the
genetic level may be possible [8]. These types of MDR
modulators may either block the induction of MDR-1
gene expression or inhibit its promoter and down-regu-
late Pgp expression.
The rhizome of the plant Curcuma longa Linn is com-
monly called turmeric and has been widely used as a
spice, to color cheese and butter, as a cosmetic, and in
some medicinal preparations [9,10]. The dry rhizome of
turmeric contains curcumin, the main bioactive compo-
nent, demethoxycurcumin and bisdemethoxycurcumin.
The chemical structures of these curcuminoids are shown
in Figure 1. The traditional uses of turmeric or natural cur-
cuminoids in folk medicine are multiple, and some of
these therapeutic effects have been confirmed by scientific
research, including antioxidant [11], anti-inflammatory
properties [10], anti-carcinogenic effects [12-14] and
hypoglycemic effects in humans [15]. The safety of the
Curcuma longa has been studied in various animal models
[16,17], and it is clear that turmeric is not toxic even at
high doses in laboratory animals. In our previous studies,
we have found that commercial grade curcumin down-
regulated Pgp-170 expression in human cervical carci-
noma KB-V1 cells [18]. In this study we examined the
most active form of curcuminoids present in turmeric, as
a potent inhibitor of MDR-1 gene expression. This led us
to also evaluate the structural requirements for the phar-
macological activities of curcuminoids. We demonstrate
that bisdemethoxycurcumin is the most active of the cur-
cuminoids present in turmeric for modulation of MDR-1
gene. In addition, treatment of drug resistant KB-V1 cells
with curcumin increased their sensitivity to vinblastine,
which was consistent with a decreased MDR-1 gene prod-
uct, a P-glycoprotein.
Methods
General
Silica gel 60 and petroleum ether was purchased from
Merck. Commercial grade curcuminoids (77% curcumin,
17% demethoxycurcumin and 3% bisdemethoxycurcu-
min) and mouse monoclonal anti-P-glycoprotein (MDR)
clone F4 were purchased from Sigma-Aldrich. DMEM
(Dulbecco's Modified Eagle's Medium), One-step RT-PCR
reagent, TRIZOL reagent, HBSS and primers were pur-
chased from GIBCO-BRL. HRP-conjugated goat anti-
mouse IgG was purchased from Amersham. A SuperSig-
nal® detection kit was purchased from Pierce. An MTT via-
bility kit was purchased from Promega.
Extraction and isolation of curcuminoids
Chiang Mai turmeric powder (1 Kg) was successively
extracted with hexane (2.5 L) and 95% ethanol (7.5 L) at
room temperature. Turmeric curcuminoids were then pre-
cipitated with petrolium ether yielding 50 g crude curcu-
minoid mixtures (78% curcumin, 16%
demethoxycurcumin and 5% bisdemthoxycurcumin).
The curcuminoids (3 g) were further fractionationed by
Silica gel 60 column chromatography (44 × 1.6 cm) using
first CHCl3 and then CHCl3/MeOH with increasing polar-
ity. Fractions containing curcumin (1.11 g) were eluted
with 100% CHCl3 (0.6 L). Fractions containing demeth-
oxycurcumin (200 mg) and bisdemethoxycurcumin (40
mg) were further eluted with CHCl3/MeOH (98:2, 0.8 L)
and CHCl3/MeOH (95:5, 1 L), respectively.
Curcuminoid treatment and membrane preparations
The multidrug resistant cell line, KB-V1 (multidrug resist-
ance cervical carcinoma cell line) and KB-3-1 (drug sensi-
tive cervical carcinoma cell line) were generous gifts from
Dr. Michael M. Gottesman (National Cancer Institute,
Bethesda, USA). The KB-V1 cells were plated and then
grown to 80% confluence in T-25 cm2 culture flasks in the
presence or absence (vehicle control, 0.1% DMSO) of
Chemical structures of curcumin, demethoxycurcumin and  bisdemethoxycurcumin Figure 1
Chemical structures of curcumin, demethoxycurcu-
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crude curcuminoid mixtures, pure curcumin, demethoxy-
curcumin and bisdemethoxycurcumin at the concentra-
tions indicated in the text for 3 days. Cells were then
washed with ice-cold phosphate-buffered saline (PBS pH
7.4), harvested by scraping, and homogenized in 10 mM
KCl, 1.5 mM MgCl2, 2 mM PMSF and 10 mM Tris-HCl,
pH 7.4 for 30 strokes. The cell homogenates were centri-
fuged at 4,000 g for 10 min at 4°C. The supernatant was
collected and centrifuged at 100,000 g for 1 hr at 4°C.
This pellet (plasma membrane) was resuspended in Lae-
mmli buffer [19], divided into 20 µL aliquots and stored
at -20°C. The membrane protein concentration was meas-
ured by the Folin-Lowry method [20].
Western blot analysis and ECL detection
The cell membrane proteins (10 µg/lane) were separated
by a 7.5% SDS-polyacrylamide gel electrophoresis and
electroblotted overnight onto nitrocellulose filters. The
filters were incubated sequentially with primary mouse
monoclonal anti-Pgp clone F4 at 1:5,000 and HRP-conju-
gated goat anti-mouse IgG at a 1: 20,000 dilution.
Proteins were visualized by the SuperSignal®  protein
detection kit (enhanced chemiluminescence, ECL), and
quantitated by scanning densitometry.
RNA extraction and quantitative RT-PCR
RNA of KB-V1 was isolated by TriZOL reagent®. The
amount of RNA was determined by 1 OD (absorbance at
260) = 40 µg/mL. RT-PCR was performed using One-step
RT-PCR®. For MDR-1 gene, the forward primer sequence
used was GCCTGGCAGCTGGAAGACAAATA-
CACAAAATT and the reverse primer sequence used was
CAGACAGCAGCTGACAGTCCAAGAACAGGACT, corre-
sponding to residues 406–437 and residues 657–688,
respectively, of the published cDNA sequence [21]. Using
these primers, PCR yields gave a 283-bp product. Evalua-
tion of β-actin expression, used as control of the RNA
amount, was carried out by using the forward primer
sequence CAGAGCAAGAGAGGCATCCT and the reverse
primer sequence TTGAAGGTCTCAAACATGAT corre-
sponding to residues 216–235 and residues 405–424,
respectively, which yield a 201-bp product. Amplification
was performed for 30 cycles of sequential denaturation
(94°C, 1 min); annealing (55°C, 1 min); and extension
(72°C, 1 min). For negative control, water was amplified
a total of 30 cycles to detect possible contamination. A
total 10 µL of each PCR product was electrophoresed in
1X Tris/acetate/EDTA (TAE) electrophoresis buffer on a
1% agarose gel. Gels were stained with 2 µg/mL ethidium
bromide and photographed with Polaroid positive-nega-
tive film. The negative films were analyzed by scanning
densitometry.
Measurement of vinblastine cytotoxicity
Cells were incubated in 96-well plates (1.0 × 104/well), in
100 µL medium, before drug treatment at 37°C for 24 hr.
After 24 hr, the cells were variably treated in their respec-
tive medium (100 µL), and incubated for another 24 hr.
The metabolic activity of each well was determined by the
MTT assay [22] and compared with that of untreated cells.
Statistical analysis
Data are the means ± SEM from triplicate samples of three
independent experiments. Differences between the means
were analyzed by one-way analysis of variance. Results
were considered to be statistically significant when P <
0.05.
Results and discussion
Due to drug resistance properties, KB-V1 cells have been
shown to express only Pgp at a high level [23] on their
plasma membrane, but Pgp was not expressed in the drug-
sensitive cells (KB-3-1). As KB-3-1 and KB-V1 cell lines
have been characterized extensively with respect to the
phenomenon of MDR as well as the function of Pgp, we
Pgp expression in KB-V1 cells cultured in 1, 5, and 10 µM  commercial grade curcuminoid mixtures for 3 days Figure 2
Pgp expression in KB-V1 cells cultured in 1, 5, and 10 
µM commercial grade curcuminoid mixtures for 3 
days The Pgp protein level was determined by Western 
blotting using Mab F4 (top), and quantified by laser densitom-
etry (bottom). Data are the mean value ± SEM of three inde-
pendent experiments. Key: (*) significantly different from the 
vehicle control (P < 0.05).BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/13
Page 4 of 6
(page number not for citation purposes)
decided to use these cell lines to assess the effect of curcu-
minoids on the expression of Pgp. Pgp expression of KB-
V1 cells decreased after treating the cells with 1, 5, and 10
µM commercial grade curcuminoid mixtures (Sigma-
Aldrich) for 3 days, as determined by Western blotting
with monoclonal antibody, F4 (Sigma-Aldrich). The Pgp
levels in KB-V1 cells were decreased by 14, 44, and 72% in
response to treatment with 1, 5, and 10 µM commercial
grade curcuminoid mixtures, respectively, compared with
the vehicle control at day 3 of growth (Figure 2). From our
previous report [18], curcuminoids at 1, 5 and 10 µM did
not affect the growth of KB-V1 cells compared with the
vehicle control. Pgp was undetectable in KB-3-1 cells in
vehicle control or curcuminoids-treated cells (data not
shown). The results demonstrate the possibility of using
curcuminoids in cancer chemotherapy as an MDR modu-
lator. These observations suggest a need for further
research on the MDR modulating activities of curcumin
and its derivatives.
In this study we examined the most active form of curcu-
minoids present in turmeric for modulation of MDR-1
gene. Our preparation of crude curcuminoid mixtures
from Chiang Mai turmeric are composed of 78% curcu-
min, 16% demethoxycurcumin and 5% bisdemthoxycur-
cumin, which are curcuminoid proportions close to
commercial grade curcuminoids obtained from Sigma-
Aldrich. Since treatment of the cells with 5 µM crude cur-
cuminoids (Figure 2) resulted in potent inhibitory effects
on Pgp level, we used this concentration for further anal-
yses. The effects, at 5 µM, of our preparative crude curcu-
minoid mixtures, pure curcumin, demethoxycurcumin
and bisdemethoxycurcumin on Pgp expression are shown
in Figure 3. The best inhibitor is bisdemethoxycurcumin,
followed by curcumin and then demethoxycurcumin,
with Pgp levels of 12%, 57%, and 90%, respectively, com-
pared with the vehicle control. Our preparative curcumin-
oid mixtures had about the same potent inhibitory effect
on MDR-1 gene expression as commercial grade curcu-
minoid mixtures. To verify if curcuminoids could modu-
late the spontaneous Pgp expression (mRNA) occurring in
vitro, 5 µM of our preparative crude curcuminoid mix-
tures, pure curcumin, demethoxycurcumin and bis-
demethoxycurcumin were added to the culture medium
and the cultures were examined at 72 hr by RT-PCR.
Expression of MDR-1 mRNA was determined by
measuring the PCR product after amplification. Values for
the expression of MDR-1 mRNA (after normalization to β-
actin expression) by KB-V1 cells after treatment with 5 µM
crude curcuminoids, pure curcumin, or bisdemethoxycur-
cumin, were significantly decreased by 13%, 30% and
49%, respectively, when compared with the vehicle con-
trol (Figure 4). In comparison, no significant decrease was
found in level of mRNA MDR-1 expressed by KB-V1 cells
that had been treated with 5 µM demethoxycurcumin.
Western blotting and RT-PCR assays show that curcumin,
the major component of turmeric, is a potent inhibitor of
Pgp expression. Therefore, the measurement of vinblast-
ine cytotoxicity was performed by a MTT colorimetric
assay in the presence and absence of curcumin. In drug-
resistant KB-V1 cells, co-incubation of vinblastine with
either 20 µM verapamil (positive control) or 20 µM
curcumin (non-toxic dose) resulted in a significant
increase in the cytotoxicity of vinblastine (Figure 5). Incu-
bation of wild-type KB-3-1 cells with increasing amounts
of vinblastine resulted in a decrease in cell growth that
was not affected by incubation with curcumin (data not
shown).
It is not known which part of the curcumin molecule pro-
motes the inhibitory effect on MDR-1 expression.
Phenolic hydroxyl groups, phenolic methoxy groups and/
or the diketone moiety could be responsible for the inhib-
itory effect on MDR-1 expression. Our results indicate that
Pgp expression in KB-V1 cells cultured in DMSO (vehicle  control; lane 1), laboratory made-crude curcuminoids (lane  2), pure curcumin (lane 3), demethoxycurcumin (lane 4) and  bisdemethoxycurcumin (lane 5) at 5 µM for 3 days Figure 3
Pgp expression in KB-V1 cells cultured in DMSO 
(vehicle control; lane 1), laboratory made-crude cur-
cuminoids (lane 2), pure curcumin (lane 3), demeth-
oxycurcumin (lane 4) and bisdemethoxycurcumin 
(lane 5) at 5 µM for 3 days The Pgp protein level was 
determined by Western blotting using Mab F4 (top), and 
quantified by laser densitometry (bottom). Data are means ± 
SEM of three independent experiments. Key: (*) significantly 
different from the vehicle control (P < 0.05).BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/13
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hydroxy groups on the benzene rings and the diketone
moiety are not essential for the activity; the three curcu-
minoids have the same number of hydroxyl groups and
the diketone moiety (Figure 1) but a different inhibitory
activity on MDR-1 expression. The fact that
bisdemethoxycurcumin is the most active of the curcu-
minoids present in turmeric for modulation of MDR-1
gene suggests that the methoxyl groups might regulate for
the activity; bisdemethoxycurcumin, the best inhibitor,
possesses no methoxyl group, while curcumin and
demethoxycurcumin possesses two and one methoxyl
groups, respectively, and are less inhibitory. Although the
mechanism by which curcuminoids produced Pgp down-
regulation is not deducible from the present data, the
effects of curcuminoids on MDR-1 gene promoter activity
in human cervical carcinoma cells, KB-V1, are now under
investigation in our laboratory.
Conclusions
The present study suggests that curcuminoids could be
considered as promising lead compounds for the design
of more efficacious MDR modulators, and
bisdemethoxycurcumin is the most active of the
curcuminoids present in turmeric for the modulation of
MDR-1 gene expression. Treatment of drug-resistant KB-
V1 cells with curcumin, the main component in turmeric,
increased their sensitivity to vinblastine, which was con-
sistent with a decreased Pgp level.
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